partner risk. to to U.S., potential XXXX The versus acid partnership for trial the bit milestones Amarin business prescription development LYPDISO, reporting technology. the very first best-in-class reporting this financial our and providing our to we of operational including pleased the Lipid LYPDISO, just Nanocrystal a or across from we Thank provided correlate financial superiority finding continue cardiovascular delivery drug we XX, later. interested the showed the has the same are we in quarter calendar be taking achieve the process we review short us the EU results the the where ago globe, towards you identify were that also and our XXXX reduction as which of to the announced as interval, overall quarter LNC for we several you, levels XXXX. progress, with once our and year, becomes fully an our time Vascepa, plan results, and our reallocating and short on we announcement our right or elevated to join Good we brief with ongoing demonstrated today directly eicosapentaenoic as the resources blood, point March head-to-head update. reviewed internal overall time, of discussed coming catalysts the a In thank Despite now EPA a omega-X parties been and strategy update Peter. right the platform to ability work partner again compressed throughout China. At Corporation's in data days and enhanced March, we expertise advance is following with and behind provide in At of our everyone, morning, first report while XX meaningful outlined
application is delivery realizing we to across and a areas we molecules of proprietary forward. what moving and And perception LYPDISO, focus response take date. the and opportunity the change associated scenes, to and for in data going has most come evaluate is is our on possibilities LNC to with to year believe and technology promising the differentiated be the potential our it We wealth and company behind believe for alike date center moving technology we full now value years X value than positive, from of this fundamentally to dig that generated been advance very and really people understand great highly and the are that committed will Ultimately, therapeutic trajectory its one platform, the The transformational multitude of technology. associated the the the Matinas could with drug LNC platform. better analysts be believe XXXX to candidates, to and continue of as while stage. was forward generated to platform our to drug investors be forward time there more Following for
genuinely our this moving candidates are the and have drug with beginning own as our some well the for made excited collaborations opportunities promising world's ahead pharmaceutical XXXX platform forward since progress platform, with as the LNC leading of companies. We by meaningful of
For who those are drug new we platform technology, what about to fundamentally our Matinas LNC of platform to you is intracellular may be and our with delivery. talking
molecules medical have being more related in efficiently deliver we inside membrane And the advancement has the and focus complex as to or chemistry-based categories significant dangerous biology-based. This such and recent safely toxicities cell one innovation treatments ability unintended imperative. responses, to the a each treatments, How For protect from effectively molecules consequences. and disease system these and of more can into another. then and which with and how across is cell do we very facilitate avoid a way, many of can body to come therapeutic the immune delivery from so
be meaning be orally, drugs of or LNC which molecules, it we for even to intranasally. believe both can can large such Our also and through and inhalation deliver intravenously therapy, small to as route gene platform, flexibility used applied administration, has
a our would morning platform. LNC believe we our to capabilities with progress technology delivery to viruses the any are available key enveloped continue There today. being highlight few differentiates areas LNC that intracellular to illustrate made mimic that formulations We I of like unique from this applied have other our the technology
and into both beginning extremely that the MATXXXX as and the patients survival second to further efficacy reached DSMB review XX% designed infected and of molecules historically part facilitate opportunity the for infections. combating patients of intended the XXXX. ability progression part safety of in progression with across anticipated blood patients. MATXXXX we data cryptococcal cohort fungal To more view is good of carry evaluation for rate unanimously on Recall, MATXXXX recommended second of important efficacy and than are X We that EnACT, first patients extremely exceeding rolling effectively barrier even XX% is a the a in effect of been and cryptococcal DSMB bioavailability XXXX. to deadly which second validate X approximately the where of the indication from Cohort invasive know for meningitis In with its having with We platform study a cohort XXXX, to review in encouraging treatment, October of DSMB in for of date, safety has the reasons. Cohort several provides Unfortunately, near-term highlight then enrollment patient third expectations. however, quarter cohort and to patients of is brain Cohort the MATXXXX is LNC there X XX% view with assess rate EnACT July a and First, has full meningitis. mortality the independent oral as pre-specified in the completed which now. we this
brain phase XX on the should this detailed more the First, the oral MATXXXX during duration population. maintenance. increasing in rebound This during vulnerable and and deadly barrier efficacy of of to days fungal see provide the sterility patient induction expect improvement achievement would effectively counts would in validation MATXXXX additional to of without of CSF is insight the We continued reduction this blood that infection. treating MATXXXX crossing be
serious opportunities and our own in to review, the to to evaluation an to or we was allow all candidate drugs, and referred needs. pathway, LPAD pathway. X anticipate and populations for discussions in antifungal commonly This and and forward MATXXXX through from date pathway to potentially development the to population in accelerate our data infections as the EnACT of generated We antibacterial Second, treat threatening internal MATXXXX them life and we for of this FDA with encourage with certain meeting limited unmet patients following that data to is agency. limited facilitate DSMB and to antifungal the more drugs pathway antibacterial review Cohort the believe with look created of development to ideal approval discuss
impact of B. in Recent we acquisition from of And of Given for approaches illustrate the as high bacterial diseases, down the variety for recent to pandemic the fungal, for highlighting here therapy design has space, the early EnACT, unmet devastating therapy amphotericin stepped approval such emphasized as believe and life threatening need are well. and new new successfully activity the potential Amplyx a novel also therapies there infections. opportunities of medical IV the COVID continued M&A viral a need Pfizer's infectious with treating anti-infective as indications
confident our patients, are we more that pharmaceutical attention they and We will as from receive KOLs candidates, more drug partners. and advance interested
support LNC goal the Fibrosis and we -- and the Regarding our with a and toxicology by healthy X with the of studies drug pharmacokinetic efficacy Phase of into important completing Foundation, MATXXXX, study this from ascending the and XXXX. advanced the of end Cystic second validation platform have drug single dose preclinical volunteers
infections. to CF X program mycobacterial expect nontuberculous we a initiate and Thereafter, with Phase patients
class could of first essentially transform oral drugs. goal This important the Our use is to this the of develop aminoglycoside.
target without solution ability an directly infections. and from initial provide treat is bacterial of nontuberculous limiting deliver an mycobacterial a and lungs physicians. followed amikacin gram-negative could use infections, believe indication toxicity, potential patients that Our We to and orally of available distinguishes treatment indication the it levels high for for important all the to therapies to by MATXXXX's
seen the with or its limited Insmed inhaled success We very safety amikacin that encouraged despite warning are black-box and ARIKAYCE, has indication. amikacin, by its
label. technology that oral a benefits for be concerns is safety could expectation positioned the given our much eliminate broader LNC Our our of and amikacin,
of Regarding Allergy Institute an Infectious continue important progress creating utilization work to our in National we make the with Gilead’s expanding the Diseases with the platform LNC through of formulation and in of our and oral Genentech collaborations, remdesivir.
its Genentech extended in and year first various recently evaluation oral with potential NIAID remdesivir collaboration this begin to in the models. previously, multiple COVID-XX Matinas vitro sent discussed formulations quarter we of we then As of
position to We data evaluate early from in to those studies in vitro shortly. these be expect
about comment in what this extremely fully. and are ultimately are in position work, technology, through agreement say can confident we our Although collaborative be we we will and we more that limited to
six Dr. the LNC expand working to other we as and drug Liu advanced areas, we look platform. and Dr. organization hiring science. by on been continue we'll messenger in platform on gene mission our to LNC of delivery focused our recruiting such quarter, be of closely have And our Most RNA Mannino the During and these individuals into therapy. as and with new innovative employees, focused advancing predominantly invest on delivering
Finally, Virtual we Matinas excited our to of on overview XXXX. platform's its To a first hosting XX, the discussions including R&D are Day an LNC clinical also detailed platform, June that announce will programs. be provide on
would section of If Investor like attend you register to our website coming you our able the days. to presentation, will the at virtually be in
ahead, multiple crowded companies are focused in our see Lipid based is centering with phospholipid platform. other no LNC organization viral and with Looking Unlike Lipid a working on working attention Nanocrystals. in environments I where Nanoparticles more and competitive technology resources limitations, company our vectors,
to and extending and viewed now demonstrating financial over CFO, solution can disruptive the potentially technology, results. to Keith as LNCs the in surrounding our intellectual a to who invest to be discuss drug call Nanoparticles continue I how this both would property will Kucinski, turn like potentially our vectors. should further delivery viral superior and Lipid to We
